NCT02002702 - Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Acute Heart Failure

Interventions

DRUG

Serelaxin

Intravenous infusion

DRUG

Placebo

Trial Locations (15)

Novartis Investigative Site, Seto

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Iizuka

Novartis Investigative Site, Hiroshima

Novartis Investigative Site, Amagasaki

Novartis Investigative Site, Higashiibaraki-gun

Novartis Investigative Site, Kanazawa

Novartis Investigative Site, Kawasaki

Novartis Investigative Site, Yokohama

Novartis Investigative Site, Sendai

Novartis Investigative Site, Ueda

Novartis Investigative Site, Osaka

Novartis Investigative Site, Sayama

Novartis Investigative Site, Komatsushimachō

Novartis Investigative Site, Itabashi-ku